ReviewJournal of immunology research2018
The Central Role of Inflammation Associated with Checkpoint Inhibitor Treatments.
Review in Journal of immunology research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma.Clinical and experimental immunology · 2019Trial
- Immunomodulatory Strategies for Managing Viral Infections in Solid Organ Transplantation: Progress and Challenges.Current microbiology · 2026Review
- Systemic STING agonist therapy drives expression of interferon stimulated genes and downstream production of cytokines in dogs with solid tumors.Journal for immunotherapy of cancer · 2025Article
- Changes in scanographic bone mineral density in melanoma patients treated with immunotherapy: a new irAE from real-life data.Scientific reports · 2025Article
- Gut Microbiota Reshapes the Tumor Microenvironment and Affects the Efficacy of Colorectal Cancer Immunotherapy.Cancer medicine · 2025Review
- Exploring pembrolizumab-induced hidradenitis suppurativa: A case-report.JAAD case reports · 2025Article
- A subpopulation of CD146Cellular & molecular immunology · 2023Article
- TNF blockade enhances the efficacy of myxoma virus-based oncolytic virotherapy.Journal for immunotherapy of cancer · 2022Article
- Article
- Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors.Journal for immunotherapy of cancer · 2021Article
- Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors.The oncologist · 2021Article
- TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis.The Journal of clinical investigation · 2021Article
- Review
- The Association Between Inflammation and Immunosuppression: Implications for ICI Biomarker Development.OncoTargets and therapy · 2021Review
- Measurement of skin viscoelasticity: A non-invasive approach in allergic contact dermatitis.Experimental and therapeutic medicine · 2020Article
- Extract from theInternational journal of molecular sciences · 2020Article
- Addition of Radiotherapy to Immunotherapy: Effects on Outcome of Different Subgroups Using a Propensity Score Matching.Cancers · 2020Article
- Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy.Cancers · 2020Article
- Leveraging Human Genetics to Identify Safety Signals Prior to Drug Marketing Approval and Clinical Use.Drug safety · 2020Article
- Pharmacokinetic Assessment ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An important function of the immune system is its ability to differentiate between healthy cells in the organism and "foreign" cells, allowing the latest to be attacked and the first ones to be conserved. The most important molecules in this process are considered to be checkpoint inhibitors. This review is focused on the association between cancer and inflammation, underlying the mechanisms of action of monoclonal antibodies that are targeting checkpoint inhibitors: ipilimumab against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and pembrolizumab and nivolumab against programmed cell death protein 1 (PD-1), their indications for treatment, and side effects. Presence of antibodies against checkpoint inhibitors shows promising results in the clinical trials in patients with types of cancer difficult to treat until now such as melanoma, non-small-cell lung cancer (NSCLC), and renal cell carcinoma, offering an increase in the overall survival rate, response rate, and progression-free rate. Resistance is now observed to emerge in patients treated with this therapy, showing the need for more studies in order to design a biomarker that will predict the type of response to immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.